Vericel (US:VCEL)2026-02-26 14:32Financial Data and Key Metrics Changes - The company reported record Q4 total revenue of $92.9 million, representing a 23% increase year-over-year, exceeding guidance for the quarter [4][15] - Full-year total revenue increased to $276.3 million, surpassing the high end of guidance [15] - Gross margin for Q4 was nearly 80%, with adjusted EBITDA margin at 40%, marking the highest quarterly margins to date [4][15] - Full-year GAAP net income grew nearly 60% to $16.5 million, with a gross margin of 74%, an increase of nearly 200 basis points compared to the prior year [16] Business Line Data and Key Metrics Changes - MACI generated record Q4 revenue of $84.1 million, reflecting a 23% increase year-over-year and 51% sequential growth from Q3 [15] - Full-year MACI revenue increased by 21% to $239.5 million [15] - Burn care Q4 revenue was $8.8 million, exceeding guidance, with full-year burn care revenue at $36.8 million [15] Market Data and Key Metrics Changes - MACI's performance showed strong growth with over 20,000 patients treated since launch, achieving a compound annual revenue growth of 24% over the past nine years [6][7] - The company noted that MACI's pricing and reimbursement profile remained strong, with prior authorization approval rates over 95% for commercial patients in 2025 [8] Company Strategy and Development Direction - The company aims to capitalize on a larger MACI sales force to increase reach and penetration within the existing surgeon base [8][9] - Strategic initiatives include enhancing commercial analytics and standardizing best practices across the sales team to drive deeper penetration [9] - The company plans to leverage MACI Arthro to drive growth in smaller cartilage defects, which represent a significant segment of MACI's addressable market [10] - The initiation of the phase III MACI Ankle MASCOT clinical study represents a substantial growth opportunity with an estimated addressable market of over $1 billion [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong momentum, expecting total company revenue of approximately $316-$326 million [17][18] - For MACI, revenue guidance is set at approximately $280-$286 million for the full year, reflecting continued growth trends [18] - The company anticipates a similar quarterly mix of MACI revenue as last year, with expectations for continued strong performance in Q1 [19] Other Important Information - The company ended the year with approximately $200 million in cash and investments, with no debt [4][16] - Management highlighted the importance of the BARDA award for NexoBrid, which could provide additional revenue opportunities [65][86] Q&A Session Summary Question: Can you discuss the balance of price versus volume for MACI? - Management indicated that both price and volume are key growth drivers, with recent performance being volume-driven, although pricing remains an important factor [24][26] Question: How does new doctor growth compare to existing customer dynamics? - Management noted that about two-thirds of trained surgeons are existing MACI users, with the remaining one-third being new adopters, and emphasized the positive growth rates among trained surgeons [27][28] Question: Can you clarify the guidance for MACI growth in 2026? - Management explained that the guidance reflects a prudent approach, with expectations for continued growth in MACI, while not baking in any significant inflection in trends [34][36] Question: What are the expectations for the sales force expansion? - Management expressed excitement about the sales force expansion, which is expected to enhance reach and performance, with productivity returning to previous levels quickly [46][47] Question: What is the outlook for NexoBrid and its adoption? - Management confirmed ongoing progress with NexoBrid, noting that they are seeing reactivation of dormant accounts and optimistic about future adoption [64][65]